FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of Regulatory Alert: The Legal Status of BPC 157 in Compounding and Clinical Practice Holt Law BPC 157 Weight Loss: Evidence & Safety BPC 157 10 mg Fair Foundations The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York BPC 157 Peptide and Lyme Disease: Tissue Repair and Immune Support